ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.703,11
-0,12%
S&P 500
5.296,69
-0,01%
Dow Jones
39.913,36
0,11%
Euro vs US Dollar
1,08539
-0,13%
Bitcoin
66.159,15
1,41%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Novan Inc (NOVN)

  7. Novan Inc (NOVN) News

NOVN

Novan (NOVN)

Novan Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:NOVN
DatumZeitQuelleÜberschriftSymbolFirma
02/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NOVNNovan Inc
02/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NOVNNovan Inc
02/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NOVNNovan Inc
01/05/202417h49Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
01/05/202417h48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
01/05/202417h44Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
01/05/202417h41Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
01/05/202417h37Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
25/03/202413h54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
26/02/202422h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
30/01/202422h47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
26/01/202422h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
05/01/202415h23GlobeNewswire Inc.Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in IndianapolisNASDAQ:NOVNNovan Inc
21/12/202322h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
11/12/202301h30GlobeNewswire Inc.Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)NASDAQ:NOVNNovan Inc
08/12/202315h15GlobeNewswire Inc.Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissionsNASDAQ:NOVNNovan Inc
06/12/202301h16GlobeNewswire Inc.Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHNASDAQ:NOVNNovan Inc
20/11/202307h15GlobeNewswire Inc.Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASHNASDAQ:NOVNNovan Inc
24/10/202323h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
20/10/202323h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
07/09/202322h58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
24/08/202322h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
26/07/202322h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
17/07/202322h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
17/07/202315h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
17/07/202314h45GlobeNewswire Inc.Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNASDAQ:NOVNNovan Inc
06/07/202323h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
28/06/202300h30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NOVNNovan Inc
16/06/202323h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NOVNNovan Inc
12/06/202315h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NOVNNovan Inc
 Showing the most relevant articles for your search:NASDAQ:NOVN

Kürzlich von Ihnen besucht

NASDAQ
NVDA
NVIDIA
NYSE
XOM
Exxon Mobil
CCOM
SILVER
SILVER
NYSE
NKE
Nike
USOTC
DTEGY
Deutsche Telekom (QX)
NASDAQ
GOOGL
Alphabet
TG
BAYN
Bayer
NASDAQ
MSFT
Microsoft
TG
MBG
MercedesBenz
NYSE
JPM
JP Morgan Chase
TG
432
Arbor Metals
NYSE
DIS
Walt Disney
AMEX
XLV
Health Care Select Sector
COIN
BTCUSD
Bitcoin
CCOM
US100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten